Company / Net Income
Serina Therapeutics, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$19.2M
FY2025
5-year range
-$19.2M / $5.3M
FY2021-FY2025
Trend
-464.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -464% YoY in FY2025, a notable deviation from the 6-year average annual change of -61%.
Based on SEC 10-K filings.
-$19M in FY2025.
Declined from $5M to -$19M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 464.1% year-over-year.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$19.2M | -464.1% |
| FY2024 | $5.3M | +0.0% |
| FY2023 | $5.3M | +150.4% |
| FY2022 | -$10.5M | -20.6% |
| FY2021 | -$8.7M | +28.6% |
| FY2020 | -$12.2M | -62.0% |
| FY2018 | -$7.5M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026